AWARD NUMBER: W81XWH-17-1-0254

TITLE: Sputum Biomarkers to Improve CT Screening for the Early Detection of Lung Cancer in Veterans

PRINCIPAL INVESTIGATOR: Feng Jiang

CONTRACTING ORGANIZATION: University of Maryland
Baltimore, MD 21201-1116

REPORT DATE: July 2018

TYPE OF REPORT: Annual report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
We propose to develop a model for identifying lung cancer in indeterminate pulmonary nodules (PNs) by integrating biomarkers, radiographic features of PNs, and clinical variables of smokers. The project’s specific aims are to (1) identify new sputum small noncoding RNA (ncRNA) biomarkers for lung cancer from the PI’s previously next-generation sequencing (NGS)-defined small ncRNA profile of lung tumors, (2) validate the previously and newly identified biomarkers and develop a prediction model by integrating the biomarkers with clinical and imaging variables for identifying NSCLC, and (3) blindly validate the prediction model for distinguishing benign from malignant growths in a different cohort of patients with low-dose computed tomography (LDCT)-discovered PNs.

The IRB protocol prepared specially for this grant was finally approved by the local VA medical system and the University of Maryland Baltimore in the early of this year. The IRB protocol was submitted to DoD. It now is reviewed. Since the DoD has not approved the IRB yet, we have not started the research experiments. We will start the planed experiments as soon as the IRB is approved by DoD.
Table of contents,

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Front cover</td>
<td>1</td>
</tr>
<tr>
<td>Standard Form (SF 298)</td>
<td>2</td>
</tr>
<tr>
<td>Table Of Contents</td>
<td>3</td>
</tr>
<tr>
<td>Introduction</td>
<td>3</td>
</tr>
<tr>
<td>Keywords</td>
<td>3</td>
</tr>
<tr>
<td>Accomplishments</td>
<td>3</td>
</tr>
<tr>
<td>Impact</td>
<td>3</td>
</tr>
<tr>
<td>Changes/Problems</td>
<td>3</td>
</tr>
<tr>
<td>Products</td>
<td>4</td>
</tr>
<tr>
<td>Participants and Other Collaborating Organizations</td>
<td>4</td>
</tr>
<tr>
<td>Special Reporting Requirements</td>
<td>4</td>
</tr>
<tr>
<td>Appendices</td>
<td>4</td>
</tr>
</tbody>
</table>

Introduction,

The IRB protocol prepared specially for this grant was finally approved by the local VA medical system and the University of Maryland Baltimore in the early of this year. The IRB protocol was submitted to DoD. It is now reviewed. Additional materials are required for HRPO to complete the review of the protocol. We are preparing the additional materials and will submit them soon. Since the DoD has not approved the IRB yet, we have not started the research experiments. We will start the planned experiments as soon as the IRB is approved by DoD.

Keywords,

Lung cancer, Veterans, small non-coding RNA, biomarkers, diagnosis.

Accomplishments,

Since the DoD has not approved the IRB yet, we have not started the research experiments. We will start the planned experiments as soon as the IRB is approved by DoD.

Impact,

No

Changes/problems, No.
Products,
No.

Participants and other collaborating organizations,
The Veterans Affairs Maryland Health Care System
The University of Maryland School of Medicine

Special reporting requirements,
No.

Appendices.
No.